Syringaresinol inhibits cardiorenal fibrosis through HSP90 in a cardiorenal syndrome type 2.
Jianjie WangJianqin ZouCheng ZhaoHan YuJiajia TengLei DongPublished in: Human & experimental toxicology (2023)
Syringaresinol targets HSP90 to suppress CRS2-induced cardiorenal fibrosis, providing a promising therapeutic drug for CRS2.